Metformin Crescent (Metformin Hydrochloride)

Metformin Crescent, a Biguanide oral hypoglycemic, acts on glucose metabolism pathways to improve glycemic control.

• Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels, aiding long‑term disease management.
• Prediabetes (impaired glucose tolerance): delays progression to overt diabetes by improving insulin sensitivity.
• Polycystic ovary syndrome: lowers insulin resistance and may help restore ovulatory function.
• Gestational diabetes (off‑label): assists in achieving maternal glycemic targets when other therapies are unsuitable.

• Metformin Hydrochloride primarily inhibits hepatic gluconeogenesis, decreasing the liver's production of glucose. It also enhances peripheral glucose uptake by increasing insulin‑mediated activation of AMP‑activated protein kinase (AMPK), which improves insulin sensitivity in muscle and adipose tissue, thereby lowering circulating blood glucose concentrations.

Metformin Crescent may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools, especially at treatment initiation.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal metabolic acidosis.
• Severe hypoglycemia: usually when combined with insulin or sulfonylureas.
• Hepatic failure: impaired liver function may exacerbate toxicity.
• Allergic reactions: rash, pruritus, or angioedema.
• Myopathy: muscle pain or weakness in rare cases.
• Electrolyte imbalance: especially with prolonged diarrhea.

Before initiating Metformin Crescent, clinicians should evaluate patient-specific risk factors and monitor therapy appropriately.

• Renal function assessment: avoid or adjust dose in patients with impaired creatinine clearance.
• Hepatic function monitoring: contraindicated in severe liver disease due to lactic acidosis risk.
• Cardiovascular status: use cautiously in heart failure or unstable angina.
• Elderly patients: start at lower dose and titrate slowly.
• Concomitant alcohol use: limit intake to reduce lactic acidosis risk.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Crescent can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.
• Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics (loop or thiazide): can affect renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Corticosteroids: may increase blood glucose, requiring dose adjustment.